Novavax, Inc. (NVAX) — closed signal from March 3, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 1, 2026.
Predicted vs. what happened
What happened
Reached 55% of the predicted growth at its peak, without hitting the target.
The thesis — published March 3, 2026
Novavax surprised with a profitable quarter and is shifting toward making money from licensing and royalties. Big partners like Sanofi and Pfizer bring cash and attention. The stock can swing a lot, so buying in stages when it dips can lower risk. If momentum continues, meaningful gains are possible over the next few months.
Primary drivers
- Profit surprise can change investor expectations
- Licensing/royalties lower dependence on one product
- Pfizer deal provides cash and credibility now
- Big price swings mean both risk and opportunity
How it played out
NVAX: rose, but never reached the target
Lyra published NVAX at 9.73 on 2026-03-03 for a short-term window ending 2026-06-01. The thesis expected 35% growth to 13.14. It pointed to a profitable quarter, a shift toward licensing and royalties, partner attention from Sanofi and Pfizer, and the stock's large price swings.
Inside the window, NVAX rose but did not reach the target. It peaked at 11.61 on 2026-05-27, with a 19.2% gain, then ended at 10.51. The move supported part of the thesis, but the target stayed out of reach. Verdict: the thesis partly played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.